NasdaqGM:PRCTMedical Equipment
PROCEPT BioRobotics (PRCT) Gains On Coverage And Trial Progress, Is The Stock Still Cheap?
PROCEPT BioRobotics (PRCT) drew fresh attention after Evercore ISI initiated coverage, alongside two new Aquablation milestones: full enrollment in the WATER IV RP trial and FDA IDE approval for a second prostate cancer study.
See our latest analysis for PROCEPT BioRobotics.
At a share price of US$23.47, PROCEPT BioRobotics has seen a 7 day share price return of 12.57% following the Evercore ISI coverage and clinical milestones, but this sits against a 1 year total shareholder return that...